Non-Small Cell Lung Cancer (NSCLC) Clinical Trials

Find Non-Small Cell Lung Cancer (NSCLC) Clinical Trials Near You

A Single-Center, Prospective Phase II Clinical Study of Stereotactic Body Proton Therapy (SBPT) for Early-Stage Non-Small Cell Lung Cancer

Status: Recruiting
Location: See location...
Intervention Type: Radiation
Study Type: Interventional
Study Phase: Not Applicable
SUMMARY

This study included patients with early-stage lung cancer cT1-3N0M0, stage IA-IIB (American Joint Committee on Cancer eighth edition staging, AJCC 8th ) who were inoperable or refused surgery. They were divided into peripheral type and central type according to the tumor location and received radical Stereotactic Body Proton Therapy (SBPT) for Early-Stage Non-Small Cell Lung Cancer. The prescribed dose for patients with peripheral lung cancer is 48-60Gray(Gy) (Relative Biological Effectiveness, RBE)/4-6 fractions, and for patients with central lung cancer, the prescribed dose is 50-70Gy(RBE)/10-15 fractions. After treatment, follow-up visits will be conducted to observe short-term and long-term efficacy, adverse reactions and patient quality of life.

Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Healthy Volunteers: f
View:

• .Lung cancer confirmed by histology and/or cytology; and in the absence of pathological diagnosis, patients who meet the following conditions can also be included: diagnosed by more than 2 imaging modalities, and the clinical diagnosis of lung cancer is confirmed after multidisciplinary team (MDT) discussion.

• The clinical staging based on positron emission tomography(PET)-computer tomography(CT) examination is: cT1\

‣ 3 N0M0, stage IA-IIB (AJCC eighth edition).

• Age: 18 years and above.

• Karnofsky(KPS) score ≥60.

• The doctor assesses that surgical treatment is not suitable or the patient refuses surgery.

• Relatively good organ function:

• Normal bone marrow function: white blood cell (WBC)≥3×109/L, Platelet ≥80×109/L, Hemoglobin(HGB)≥90g/L

• Normal liver and kidney function:

• Total bilirubin, Aspartate Aminotransferase(AST), and ALT(Alanine Aminotransferase)≤2.0×upper limit of normal values;

⁃ Creatinine clearance ≥60ml/min or creatinine ≤1.5×upper limit of normal value

⁃ The patient has signed an informed consent form and is willing and able to comply with planned study visits, treatment plans, laboratory tests, and other study procedures.

Locations
Other Locations
China
Guangzhou Concord Cancer Center
RECRUITING
Guangzhou
Contact Information
Primary
Taize Yuan Professor, Doctor
taize.yuan@ccm.cn
8620-32506160
Time Frame
Start Date: 2026-02-24
Estimated Completion Date: 2029-07-01
Participants
Target number of participants: 65
Treatments
Experimental: Stereotactic Body Proton Therapy
The prescribed dose for patients with peripheral lung cancer is 48-60Gy(RBE)/4-6 fractions, and for patients with central lung cancer, the prescribed dose is 50-70Gy(RBE)/10-15 fractions.
Sponsors
Leads: Guangzhou Concord Cancer Center

This content was sourced from clinicaltrials.gov